EMA accepts Teva’s Fremanezumab Marketing Authorization Application
Teva Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for fremanezumab, an anti-calcitonin gene-related…
Read More...
Read More...
